Halozyme Therapeutics Inc (HALO)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 348,329 | 248,918 | 248,518 | 129,302 | -72,251 |
| Revenue | US$ in thousands | 809,880 | 641,313 | 435,810 | 267,594 | 195,992 |
| Pretax margin | 43.01% | 38.81% | 57.02% | 48.32% | -36.86% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $348,329K ÷ $809,880K
= 43.01%
The pretax margin of Halozyme Therapeutics Inc. has shown fluctuating trends over the past five years. In 2023, the pretax margin increased to 42.01% from 37.71% in 2022, indicating an improvement in the company's ability to generate profits before taxes relative to its revenue. However, compared to the exceptionally high pretax margin of 56.06% in 2021, the 2023 margin was lower.
The negative pretax margin of -36.86% in 2019 is a concerning outlier, suggesting that the company faced significant challenges or incurred exceptional expenses that year. The subsequent improvement in the pretax margin in the following years indicates a recovery and possibly the implementation of effective cost-control measures or revenue-generating strategies.
Overall, the pretax margin analysis highlights the company's ability to manage its operating expenses and generate profits before tax, although further investigation into the factors driving these fluctuations would be necessary to provide a more detailed assessment of Halozyme Therapeutics Inc.'s financial performance.
Peer comparison
Dec 31, 2023